Nemaura Medical Inc. (NMRD)
OTCMKTS: NMRD · Delayed Price · USD
0.0542
-0.0025 (-4.39%)
Apr 26, 2024, 1:27 PM EDT - Market closed
Nemaura Medical Revenue
Nemaura Medical had revenue of $-1.55M in the twelve months ending December 31, 2023, down -490.98% year-over-year. In the fiscal year ending March 31, 2023, Nemaura Medical had annual revenue of $77.04K, a decrease of -84.71%.
Revenue (ttm)
$-1.55M
Revenue Growth
-490.98%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
1.57M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 77.04K | -426.86K | -84.71% |
Mar 31, 2022 | 503.91K | - | - |
Mar 31, 2021 | 0 | - | - |
Mar 31, 2020 | 0 | - | - |
Mar 31, 2019 | 0 | - | - |
Mar 31, 2018 | 0 | - | - |
Mar 31, 2017 | 0 | - | - |
Mar 31, 2016 | 0 | - | - |
Mar 31, 2015 | 0 | - | - |
Mar 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
NMRD News
- 4 months ago - Important Update on Listing Status and Strategic Direction - GlobeNewsWire
- 4 months ago - Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision - GlobeNewsWire
- 5 months ago - Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth - GlobeNewsWire
- 5 months ago - Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs - GlobeNewsWire
- 5 months ago - Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs. - GlobeNewsWire
- 7 months ago - Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference - GlobeNewsWire
- 8 months ago - Nemaura Medical Provides Update on Nasdaq Compliance Status and Process - GlobeNewsWire